Prevalence of NCD Risk Factors in Kazakhstan

Preventive and Personalized Medicine (2021-2023)

This is a cross-sectional study that aims to study the prevalence of risk factors of noncommunicable diseases in people aged 18 to 69 years using the standardized and adopted STEPS questionnaire in the Republic of Kazakhstan.

Study Overview

• Status: Completed
• Conditions: Non-Communicable Chronic Diseases
• Intervention / Treatment: Diagnostic test: Blood test; Diagnostic test: STEPwise Approach to NCD Risk Factor Surveillance (STEPS); Diagnostic test: Spirometry

Detailed Description

The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids.

• Study Type: Observational
• Enrollment (Actual): 20400

Contacts and Locations

Study Locations

• Kazakhstan
  • Almaty, Kazakhstan, 050020
    • Kazakhstan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 69 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All ethnic groups in Kazakhstan

Description

Inclusion Criteria:

• Age Limits 18-69 years

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

The study Group; Population of Kazakhstan

Diagnostic test: Blood test; Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott); Diagnostic test: STEPwise Approach to NCD Risk Factor Surveillance (STEPS); The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.; Diagnostic test: Spirometry; Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
tobacco use	currently smoke tobacco, currently smoke tobacco daily, age started smoking, daily smokers smoking manufactured cigarettes	1 year
alcohol consumption	lifetime abstainers, past 12 month abstainers, currently drink (drank alcohol in the past 30 days), heavy episodic drinking (6 or more drinks on any occasion in the past 30 days).	1 year
physical activity	insufficient physical activity (defined as < 150 minutes of moderate-intensity activity per week, or equivalent), physical activity on average per day (minutes), not engaging in vigorous activity.	1 year
unhealthy diet	days fruit consumed in a typical week, servings of fruit consumed on average per day, days vegetables consumed in a typical week, servings of vegetables consumed on average per day, less than 5 servings of fruit and/or vegetables on average per day, always or often add salt or salty sauce to their food before eating or as they are eating, always or often eat processed foods high in salt.	1 year
BMI	overweight (BMI ≥ 25 kg/m2), obese (BMI ≥ 30 kg/m2), normal weight	1 year
raised blood pressure	systolic blood pressure - SBP (mmHg), including those currently on medication for raised BP, diastolic blood pressure - DBP (mmHg), including those currently on medication for raised BP, raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP), raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP) who are not currently on medication for raised BP.	1 year
raised blood glucose	fasting blood glucose, including those currently on medication for raised blood glucose, impaired fasting glycaemia (plasma venous value ≥6.1 mmol/L (110 mg/dl) and <7.0 mmol/L (126 mg/dl)), raised fasting blood glucose (plasma venous value ≥ 7.0 mmol/L (126 mg/dl)) or currently on medication for raised blood glucose.	1 year
abnormal blood lipids	total blood cholesterol, including those currently on medication for raised cholesterol, raised total cholesterol,	1 year

Collaborators and Investigators

• Sponsor: Asfendiyarov Kazakh National Medical University
• Investigators: Principal Investigator: Timur M Saliev, S.D. Asfendiyarov Kazakh National Medical University; Study Director: Mukhtar B Kulimbet, MD/MSc, S.D. Asfendiyarov Kazakh National Medical University; Principal Investigator: Zhumaly A Kauyzbay, PhD, AP, Joint Stock Company - South Kazakhstan Medical Academy; Principal Investigator: Samat S Saparbayev, PhD, West Kazakhstan Marat Ospanov Medical University; Principal Investigator: Alma U Nurtazina, MD/PhD, NCJSC Semey Medical University; Principal Investigator: Bayan A Ainabekova, MD/DMSc, NCJSC Astana Medical University; Principal Investigator: Anar A Turmukhambetova, DMSc, NCJSC Karaganda Medical University; Principal Investigator: Maksut K Kulzhanov, DMSc, Kazakhstan's Medical University "KSPH"; Study Chair: Ildar Fakhradiyev, PhD, S.D. Asfendiyarov Kazakh National Medical University

Study record dates

Study Major Dates

• Study Start (Actual): October 23, 2021
• Primary Completion (Actual): August 20, 2022
• Study Completion (Actual): August 20, 2022

Study Registration Dates

• First Submitted: September 29, 2021
• First Submitted That Met QC Criteria: November 4, 2021
• First Posted (Actual): November 17, 2021

Study Record Updates

• Last Update Posted (Actual): March 14, 2023
• Last Update Submitted That Met QC Criteria: March 13, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Chronic Disease; Noncommunicable Diseases
• Other Study ID Numbers: 1197

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No